Alpha-9 Theranostics is a clinical-stage radiopharmaceutical company developing differentiated and highly targeted radiopharmaceuticals to treat people living with cancer. The company applies proprietary technologies and expertise in peptide and small-molecule modification to engineer bespoke radiopharmaceuticals optimized to selectively deliver radiation to tumor sites while minimizing off-target effects. Alpha-9 is advancing a pipeline of novel radiopharmaceuticals with a systematic approach to molecule design that offers potential to expand into several validated oncology targets. Founded in 2019 by researchers from BC Cancer and the University of British Columbia, the team has deep expertise in radiopharmaceutical design. The company recently raised $75M in a Series B financing to support its development activities. Alpha-9 plans to use the proceeds to advance five programs into the clinic over the next two years while expanding its early-stage programs. Alpha-9 Theranostics is a clinical-stage radiopharmaceutical company developing imaging and therapeutic molecules for solid and hematologic malignancies. The company uses proprietary technology to create differentiated imaging and therapeutic molecules intended to extend patients’ lives with favorable safety profiles. Alpha-9 was founded by researchers from the University of British Columbia and BC Cancer with the goal of improving outcomes for patients affected by metastatic cancers. The company plans to advance a portfolio of novel radiotherapeutics and diagnostics and move multiple programs into clinical trials. In April 2021 Alpha-9 announced an $11 million Series A financing to support advancement of its programs.

Total raised

$86M

Funding rounds

2

Latest round

Series B

Latest activity

Dec 2022